Among Rockefeller University’s new life science funding is a $2.4 million grant from the NIH that will be used to fund a study involving integrating innate and adaptive pathways in vaccine response. The funding organization within the NIH that awarded this life science grant is the National Institute of Allergy and Infectious Diseases, and the project start date was April 1st, 2014.
“The goal of this program is to perform directed investigations into the evolution of lasting, protective immune responses in humans in order to better understand the requirements of effective vaccines and adjuvants,” states the NIH Project Information page. “This application is submitted to obtain funding for a Cooperative Center on Human Immunology at The Rockefeller University. Our program is highly integrated and is based on long-term, productive collaborations between the PIs on defining underlying principles of human immunology, utilizing the infrastructure of the Rockefeller University Hospital, the Zanvil Cohn Vaccine Center and the Rockefeller University Clinical and Translational Science Award (CTSA).”
The project leader among researchers receiving this latest life science grant is Dr. Jeffrey Ravetch. Dr. Ravetch examines cellular responses by looking directly at the cellular and molecular mechanisms in charge of antibody specificity. His general research goals are to better understand how a functioning immune system protects organisms from invasive agents, and how a negatively affected immune system attacks tissues within a patient’s own body.
Dr. Ravetch
Image courtesy of Rockefeller University
"The proposed research projects are designed as hypothesis-testing, mechanistic studies, examining novel aspects of the activation and regulation of human immune responses in the context of vaccination against infectious disease,” researchers said of the project receiving the new NIH life science grant. “The participating investigators are pioneers in identifying and characterizing basic mechanisms of the human immune response, having contributed to the initial characterizations of the dendritic cell, the diversity of IgG antibody effector functions add description of Fc receptors as mediators of immunity, the development of the first models for study of the hepatitis C virus and the identification of multiple HCV receptors.”
In addition to receiving this latest life science grant, Rockefeller University will be using $240 million in life science funding to build a new two-story, 160,000 square foot laboratory building. Biotechnology Calendar, Inc. wrote a spotlight story on this new building last week. The process of building the facility is officially underway after New York City approved plans for construction.
If you are a lab supplier working to market lab supplies and get the word out on your life science solutions in New York, Biotechnology Calendar, Inc.’s life science vendor show at Rockefeller University is the perfect opportunity to do so. The BioResearch Product Faire™ Event at Rockefeller University will take place on October 1st, 2014. Last year, this life science vendor show attracted 513 attendees. Of these attendees, 111 were purchasing agents, professors and post docs, and 49 were lab managers. The visitors came from 24 different research buildings and 65 on-campus departments.
Biotechnology Calendar, Inc. is a full-service science research marketing and events-planning company that organizes life science vendor shows at top research universities across the United States. We have been in the business of helping lab suppliers market lab supplies and life science solutions for over 20 years. If you are interested in exhibiting at a life science vendor show closer to home, we encourage you to visit our 2014 calendar of events. For more life science funding information on Rockefeller University, or to learn more about our Rockefeller life science vendor show, click on the button below.
